Board of Directors
Clinical Trials conducted to date
Systemic Lupus Erythematosus
News & Media
Investor and Media Contact
Invion announces Underwritten Rights Issue
Appendix 4C – December 2017 Quarter
Appendix 3B: issue of New Shares following Shareholder Resolution at AGM
Invion is a life sciences company focussed on the development of treatments for major opportunities in inflammatory diseases. Invion is an ASX listed company (ASX:IVX), with operations in Brisbane, Australia and Delaware, USA.
Invion has an agreement to conduct clinical development of Photosoft™ globally, with The Cho Group will providing non-dilutive funding for R&D and clinical trials as part of a global development strategy. Invion has been granted exclusivity in Australia and New Zealand to commercialise and distribute Photosoft™ for the treatment of cancers.
Invion Limited – Targeting Inflammation